Categories: NewsSports medicine

Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at 11:10 a.m. ET on Tuesday, March 5, 2024.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contacts:

Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com 

Staff

Recent Posts

TODAY SHOW EXPOSES AI MEDICAL SCAMS TARGETING LIPEDEMA PATIENTS

LOS ANGELES, Dec. 5, 2025 /PRNewswire/ -- AI-generated deepfake scams are rapidly spreading across social media,…

20 minutes ago

Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc.

Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / December 5, 2025…

3 hours ago

Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc.

Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / December 5, 2025…

3 hours ago

Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink:…

6 hours ago

Techficient Launches Surefire, Its Proprietary Modern Underwriting Engine

BOISE, Idaho, Dec. 5, 2025 /PRNewswire/ -- Techficient, a leading innovator in Insurtech solutions, announces the…

6 hours ago

Clinical Education Alliance Becomes Decera Clinical, Delivering Education, Insights, and Communications

Company brings its Scientific Activation™ mission to life at ASH Annual Meeting following November rebrand RESTON,…

6 hours ago